课题基金 / 基金详情

The prediction of Helicobacter Pylori eradication using CYP2C19 activity determined by limited plasma concentration of omeprazole enantiomers

The prediction of Helicobacter Pylori eradication using CYP2C19 activity determined by limited plasma concentration of omeprazole enantiomers
利用奥美拉唑对映体有限血浆浓度确定的 CYP2C19 活性预测幽门螺杆菌根除
批准号:
20590150
负责人:
UNO Tsukasa
金额:
$2.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2010

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Until now, no studies investigating the in vivo metabolic behaviour of omeprazole enantiomers have been reported. The three major metabolites of omeprazole, known as (R)-,(S)-5-hydroxyomeprazole and omeprazole sulfone, are mainly metabolised by cytochrome P450 (CYP) 2C19 and CYP3A4, respectively. The clinical efficacy of Helicobacter Pylori eraducation is closely related to the CYP2C19 phenotypes, as evidenced by studies in patients receiving omeprazole. In the present study, we constructed a simple and sensitive high-performance liquid chromatography (HPLC) UV method and it used in pharmacokinetic studies of (R)- and (S)-omeprazole and their chiral metabolites in relation to the CYP2C19 genotypes. Conceqently, CYP2C19 genotypes were clarified and the prediction of CYP2C19 genotypes by using limited plasma concentration of omeprazole enantiomers may be a important tool in clinical situation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PGP-MEDIATED EFFECTS OF ITRACONAZOLE AND CARBAMAZEPINE ON FEXOFENADINE ENANTIOMERS PHARMACOKINETICS
PGP 介导的伊曲康唑和卡马西平对非索非那定对映体药代动力学的影响
DOI: --
发表时间: 2009
期刊:
影响因子: --
作者: [Niioka T, Miura M, Uno I, Yasui-Furukori N, Hayakari M, Tateishi T, Suzuki T, 潮平英郎, 潮平英郎, 赤嶺由美子]
通讯作者: 赤嶺由美子
DOI: 10.1038/ja.2011.46
发表时间: 2011-08
期刊: The Journal of Antibiotics
影响因子: --
作者: [S. Sunagawa;J. Fujita;F. Higa;M. Tateyama;Shusaku Haranaga;I. Nakasone;N. Yamane;Tsukasa Uno]
通讯作者: S. Sunagawa;J. Fujita;F. Higa;M. Tateyama;Shusaku Haranaga;I. Nakasone;N. Yamane;Tsukasa Uno
The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers
CYP2C19基因型对华法林对映体药代动力学的影响
DOI: --
发表时间: 2008
期刊: Journal of Clinical Pharmacy and Therapeutics
影响因子: 2
作者: [T. Uno, K. Sugimoto, K. Sugawara, T. Tateishi]
通讯作者: T. Tateishi
ラベプラゾールとその主代謝物の高感度定量によるCYP2C19遺伝子型に関連したCYP3AまたはP-gp阻害剤とのin vivo併用効果
雷贝拉唑及其主要代谢物与CYP3A或P-gp抑制剂的体内联合作用与CYP2C19基因型的关系
DOI: --
发表时间: 2008
期刊:
影响因子: --
作者: [Niioka T, Miura M, Uno I, Yasui-Furukori N, Hayakari M, Tateishi T, Suzuki T, 潮平英郎, 潮平英郎, 赤嶺由美子, 赤嶺由美子, 外間惟夫]
通讯作者: 外間惟夫
20
    海外基金